MYC and hematologic disorder: Although the development of small molecules inhibiting MYC activity has been difficult, several MYC-directed therapies, including bromodomain, extraterminal (BET) inhibitors, and the Omomyc peptide, have been assessed in preclinical settings and in clinical trials (NCT01713582) involving hematological malignancies with durable responses51,52.